LID.L Regulatory News (LID)

3 Nov 2005 07:00

LiDCO Group Plc03 November 2005 For immediate release 3 November 2005 LIDCO GROUP PLC ("LiDCO" or "the Company") LIDCO'S LARGEST EVER US ORDER FOR MONITORS 3 November 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoringcompany, is pleased to announce that the United States Army has purchased 31LiDCO(TM)plus Continuous Hemodynamic Monitors to be used in 16 major medicalcenters in and outside the U.S. This order of $456,000 for 31 LiDCOplus Monitorsis the largest received to date by our US sales organisation. It follows on fromthe successful conclusion of an evaluation conducted at Brooke Army MedicalCenter, Texas. Lt. Col. Kurt Grathwohl MD, Assistant Chief of Anesthesia at Brooke Army MedicalCenter, who co-ordinated the purchase with the US MeDCom Surgeon General,stated: "We are looking forward to utilizing the LiDCO(TM)plus System in ourfacilities. The use of these monitors will provide immediate and more accuratehemodynamic information allowing us to better treat and optimize our criticallyill patients." Dr Terry O'Brien, Chief Executive of LiDCO, stated: "This order is a tremendousendorsement for the use of our technology. We would like to thank the US Armyfor choosing our system and products. We are excited about working with thedoctors and nurses in these centres to implement our novel standard of care inminimally invasive hemodynamic monitoring." For more information please contact: LiDCO Group Plc Tel: +44 (0)20 -7749 1500Terry O'Brien (CEO), Hugh McGarel-Groves (FD) Buchanan Communications Tel: +44 (0)20 7466 5000Tim Anderson, Mary-Jane Johnson, James Strong Panmure Gordon Tel: +44 (0)20 7459 3600Grant Harrison, Aubrey Powell, Katherine Roe About LiDCO Group Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in London, UK and its current productsare: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets inEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care -(Early Good Directed Therapy) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000per patient. Extrapolated nationally, this would equate to a estimated savingof £500 million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significantreduction in medical complications (particularly infections) through the use ofLiDCO's minimally invasive technology to improve tissue oxygen levels followingsurgery. This information is provided by RNS The company news service from the London Stock Exchange